Medical/Pharmaceuticals
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening
- Lunit's collaborative study supports AI as a viable alternative to one human reader inEurope's double reading system - published in The Lancet Digital Health SEOUL, South Korea, Sept. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnosti...
2023-09-11 21:00
1794
Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...
2023-09-11 15:00
1258
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
SHANGHAI, Sept. 8, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell's multiple ADC projects. Mabwell has...
2023-09-08 15:30
1623
World Orphan Drug Alliance Welcomes Specialised Therapeutics
* SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases. * ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA). * Wor...
2023-09-08 04:00
1726
SOAP Health and AESOP Technology Unite to Provide Advanced AI Solutions for Clinical Decision-Support and Medical Coding
SOAP Health's conversational AI for medical encounters, risk and symptom assessment, and documentation integrates with AESOP Technology's electronic medical record data analysis for clinical decision optimization, coding, and productivity. BOCA RATON, Fla., Sept. 7, 2023 /PRNewswire/ -- SOAP Hea...
2023-09-07 21:00
1592
United Imaging Confirms Installation of Country's First uMI Panorama™ at Huntsman Cancer Institute
The award-winning 12-year old manufacturer and widely-recognized leading cancer center agreed to install United Imaging's recently unveiled innovation. HOUSTON, Texas, Sept. 7, 2023 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced t...
2023-09-07 21:00
1469
Isotopia Issues a call to action to the radionuclide Therapy industry.
PETAH TIKVA, Israel, Sept. 6, 2023 /PRNewswire/ -- Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes therapeutic and diagnostic radioactive isotopes. "If you are in the Lu-177 field, don't miss this information." The Lu-177 radiopharmaceutical...
2023-09-06 20:40
1634
Health In Tech Introduces New Ancillary Products to Expand Healthcare Solutions
Expands Health Care offerings with Critical Illness, Accident, Dental, Vision, Term Life, and Gap coverage options. STUART, Fla., Sept. 6, 2023 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is e...
2023-09-06 20:30
1593
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 6, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment o...
2023-09-06 20:00
1359
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
* The first and only anti-PD-1 antibody approved for treating cervical cancer inChina * ORR of 27.8%, mPFS of 3.7m, and mOS of 16.8m achieved as monotherapy with best-in-class potential * A Phase 3 trial (VICT-004) of zimberelimab in combination with platinum-based chemotherapy +/- bevacizu...
2023-09-06 19:00
1418
CANbridge to Participate in Two Investor Conferences in September
BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today a...
2023-09-06 16:06
1641
Exosomes functionally deliver siRNAs in vivo to repress tumor growth
SUZHOU, China, Sept. 5, 2023 /PRNewswire/ -- VesiCURE Therapeutics Co. Ltd., a biotechnology company located in Suzhou,China, recently released a preprint on BioRxiv titled "Harnessing extracellular vesicles for efficient siRNA delivery in vitro and in vivo" (doi:https://doi.org/10.1101/2023.0...
2023-09-05 21:20
1763
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages. Compared with other commercially available hyaluronidase products, Tergase® showed no incidence of anti-drug antibodies (ADA). The occurrence of ADA is known ...
2023-09-05 20:00
1295
David Topper Joined Inmagene as CFO
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced the appointment ofDavid Topper as Chief Financial Officer (C...
2023-09-05 20:00
1616
I-Mab Announces Upcoming Participation at September Conferences
ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies an...
2023-09-05 20:00
1419
Baird Medical's Single-Use Sterile Biopsy Needle Receives Approval from Jiangsu Medical Products Administration in China
GUANGZHOU, China, Sept. 5, 2023 /PRNewswire/ -- Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina, today announced that its subsidiary, Nanjing Changcheng Medical Equipment Co., Ltd., h...
2023-09-05 17:00
1280
Signia Introduces Hearing Aids That Tackle the Most Difficult Challenge for People With Hearing Loss: Group Conversations in Noise
LYNGE, Denmark, Sept. 5, 2023 /PRNewswire/ -- Hearing aid innovator Signia, part of WS Audiology, today launchesIntegrated Xperience, a breakthrough technology that enables hearing aid wearers to hear all speakers in noisy group conversations clearly. Even when speakers move or the wearer turns t...
2023-09-05 14:00
1238
GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS)
* The first clinical trial sample analysis provider to adopt LIMS * To provide enhanced quality of pharmacokinetic, pharmacodynamic, and immunogenicity data from bioanalytic testing YONGIN, South Korea, Sept. 4, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, annou...
2023-09-05 09:57
1345
Game-changing Virtuoso Digital Front Door technology radically rewires healthcare
World-first technology launches to unlock preventative, proactive and predictive healthcare BOSTON, Sept. 4, 2023 /PRNewswire/ -- Global leader in population health, Orion Health, is ushering in the next era of health – moving from institution-centric reactive sick care to people-centered preven...
2023-09-04 21:00
1684
ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors
SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignan...
2023-09-02 00:00
3177
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6494
